Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension
Status: Enrolling
Updated:  7/13/2016
Clinical Research Facility
mi
from
Seattle, WA
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension
Status: Enrolling
Updated: 7/13/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension
Status: Enrolling
Updated:  7/13/2016
Clinical Research Facility
mi
from
Green Bay, WI
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension
Status: Enrolling
Updated: 7/13/2016
Clinical Research Facility
mi
from
Green Bay, WI
Click here to add this to my saved trials
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension
Status: Enrolling
Updated:  7/13/2016
Clinical Research Facility
mi
from
Milwaukee, WI
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension
Status: Enrolling
Updated: 7/13/2016
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension
Status: Enrolling
Updated:  7/13/2016
Research Site
mi
from
La Louviere,
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension
Status: Enrolling
Updated: 7/13/2016
Research Site
mi
from
La Louviere,
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
Loma Linda University Dept. of Neurology
mi
from
Loma Linda, CA
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
Loma Linda University Dept. of Neurology
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
UCLA School of Medicine Dept. of Neurology
mi
from
Los Angeles, CA
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
UCLA School of Medicine Dept. of Neurology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
University of California at San Francisco
mi
from
San Francisco, CA
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
University of Colorado Health Sciences
mi
from
Denver, CO
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
University of Colorado Health Sciences
mi
from
Denver, CO
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
University of Miami Dept. of Neurology
mi
from
Miami, FL
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
University of Miami Dept. of Neurology
mi
from
Miami, FL
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
Northwestern Medical School
mi
from
Chicago, IL
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
Northwestern Medical School
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
Johns Hopkins University
mi
from
Baltimore, MD
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
Massachusetts General Hospital
mi
from
Boston, MA
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
Columbia-Presbyterian Center Neurological Institute
mi
from
New York, NY
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
Columbia-Presbyterian Center Neurological Institute
mi
from
New York, NY
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
State University of New York
mi
from
Syracuse, NY
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
State University of New York
mi
from
Syracuse, NY
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
Carolinas Medical Center Carolinas Neuromuscular/ALS-MDA Center
mi
from
Charlotte, NC
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
Carolinas Medical Center Carolinas Neuromuscular/ALS-MDA Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
Wake Forest University
mi
from
Winston-Salem, NC
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
MCP-Hahnemann University Dept. of Neurology
mi
from
Philadelphia, PA
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
MCP-Hahnemann University Dept. of Neurology
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
Penn Neurological Institute
mi
from
Philadelphia, PA
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
Penn Neurological Institute
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  7/13/2016
University of Wisconsin ALS Clinical Research Center
mi
from
Madison, WI
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 7/13/2016
University of Wisconsin ALS Clinical Research Center
mi
from
Madison, WI
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Barrow Neurological Institute
mi
from
Phoenix, AZ
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Barrow Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
George Washington University Medical Faculty Associates
mi
from
Washington,
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
George Washington University Medical Faculty Associates
mi
from
Washington,
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Neurological Associates
mi
from
Ft. Lauderdale, FL
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Neurological Associates
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Neurology & Headache Specialist of Atlanta, L.L.C.
mi
from
Decatur, GA
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Neurology & Headache Specialist of Atlanta, L.L.C.
mi
from
Decatur, GA
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Radiant Research Alexian Brothers
mi
from
Elk Grove Village, IL
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Radiant Research Alexian Brothers
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Consultants in Neurology, Ltd.
mi
from
Northbrook, IL
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Consultants in Neurology, Ltd.
mi
from
Northbrook, IL
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Advanced Neurology Specialists
mi
from
Great Falls, MT
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Advanced Neurology Specialists
mi
from
Great Falls, MT
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Neurological Associates, P.C.
mi
from
Lincoln, NE
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Neurological Associates, P.C.
mi
from
Lincoln, NE
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Upstate Clinical Research, LLC
mi
from
Albany, NY
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Upstate Clinical Research, LLC
mi
from
Albany, NY
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
DENT Neurologic Group L.L.P.
mi
from
Amherst, NY
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
DENT Neurologic Group L.L.P.
mi
from
Amherst, NY
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Hospital for Joint Diseases - MS Care Center
mi
from
New York, NY
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Hospital for Joint Diseases - MS Care Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Institute For Human Performance
mi
from
Syracuse, NY
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Institute For Human Performance
mi
from
Syracuse, NY
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Raleigh Neurology Associates
mi
from
Raleigh, NC
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Raleigh Neurology Associates
mi
from
Raleigh, NC
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
NeuroCare Center, Inc.
mi
from
Canton, OH
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
NeuroCare Center, Inc.
mi
from
Canton, OH
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Leheigh Valley Neurosciences and Pain Research Center
mi
from
Allentown, PA
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Leheigh Valley Neurosciences and Pain Research Center
mi
from
Allentown, PA
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Westmorland Neurology
mi
from
Greensburg, PA
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Westmorland Neurology
mi
from
Greensburg, PA
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Neurological Associates of Delaware Valley
mi
from
Upland, PA
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Neurological Associates of Delaware Valley
mi
from
Upland, PA
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
FACH-UHC Department of Neurological Services
mi
from
Burlington, VT
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
FACH-UHC Department of Neurological Services
mi
from
Burlington, VT
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Swedish Medical Center
mi
from
Seattle, WA
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Neurology and Neurosurgery Associates of Tacoma
mi
from
Tacoma, WA
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Neurology and Neurosurgery Associates of Tacoma
mi
from
Tacoma, WA
Click here to add this to my saved trials
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated:  7/13/2016
Barrow Neurological Institute
mi
from
Phoenix, AZ
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated: 7/13/2016
Barrow Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated:  7/13/2016
Center for Neurologic Study
mi
from
La Jolla, CA
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated: 7/13/2016
Center for Neurologic Study
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated:  7/13/2016
UCLA School of Medicine
mi
from
Los Angeles, CA
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated: 7/13/2016
UCLA School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated:  7/13/2016
UCSF
mi
from
San Francisco, CA
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated: 7/13/2016
UCSF
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated:  7/13/2016
Research Center for Clinical Studies, Inc.
mi
from
Darien, CT
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated: 7/13/2016
Research Center for Clinical Studies, Inc.
mi
from
Darien, CT
Click here to add this to my saved trials
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated:  7/13/2016
George Washington University Medical Faculty Assoc
mi
from
Washington,
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated: 7/13/2016
George Washington University Medical Faculty Assoc
mi
from
Washington,
Click here to add this to my saved trials
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated:  7/13/2016
Neurological Associates
mi
from
Ft. Lauderdale, FL
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated: 7/13/2016
Neurological Associates
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated:  7/13/2016
University of Miami Dept. of Neurology
mi
from
Miami, FL
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated: 7/13/2016
University of Miami Dept. of Neurology
mi
from
Miami, FL
Click here to add this to my saved trials
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated:  7/13/2016
Miami Jewish Home and Hospital for the Aged
mi
from
Miami, FL
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Status: Enrolling
Updated: 7/13/2016
Miami Jewish Home and Hospital for the Aged
mi
from
Miami, FL
Click here to add this to my saved trials